SCHEMBL5446339

SCHEMBL5446339

O=C(NO)c1cc(CS(=O)(=O)c2cccc(Cl)c2)on1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.50
NPC1 O15118 4/20 0.50
RAB9A P51151 4/20 0.50
KMT2A Q03164 3/20 0.50
MEN1 O00255 2/20 0.50
HTT P42858 2/20 0.50
MAPT P10636 3/20 0.48
MAPK1 P28482 2/20 0.48
LMNA P02545 1/20 0.46
HDAC6 Q9UBN7 10/20 0.46
HDAC1 Q13547 5/20 0.44
HDAC4 P56524 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC11 Q96DB2 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC9 Q9UKV0 1/20 0.44
HDAC5 Q9UQL6 1/20 0.44
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5445146 0.86 SMN1; SMN2 (0.57) SMN1; SMN2NPC1RAB9AKMT2AMEN1
SCHEMBL5451039 0.82 NPC1 (0.53) SMN1; SMN2NPC1RAB9AHTTMAPT
SCHEMBL5449570 0.79 SMN1; SMN2 (0.57) SMN1; SMN2NPC1RAB9AKMT2AMEN1
SCHEMBL5446344 0.74 L3MBTL1 (0.60) SMN1; SMN2NPC1RAB9AKMT2AMEN1
SCHEMBL5456527 0.71 HDAC6 (0.46) SMN1; SMN2NPC1RAB9AMAPK1LMNA
SCHEMBL4945191 0.67 NOTUM (0.67) SMN1; SMN2NPC1RAB9AKMT2AMEN1
SCHEMBL2069565 0.67 EDNRB (0.45) SMN1; SMN2NPC1RAB9AKMT2AMEN1
SCHEMBL5451531 0.67 MEN1 (0.56) SMN1; SMN2NPC1RAB9AKMT2AMEN1
SCHEMBL20524096 0.66 HDAC6 (0.56) SMN1; SMN2NPC1RAB9AHDAC6HDAC1
SCHEMBL21939043 0.66 THRB (0.56) SMN1; SMN2NPC1RAB9AMAPTHDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043062-A1 Isoxazoles as peptide deformylase inhibitors ARPIDA A/S (DK) 2007-02-22 US claimed
EP-1664000-A1 ISOXAZOLES AS PEPTIDE DEFORMYLASE INHIBITORS Arpida A/S (DK) 2006-06-07 EP claimed
WO-2005026133-A1 ISOXAZOLES AS PEPTIDE DEFORMYLASE INHIBITORS ARPIDA A/S (DK) 2005-03-24 WO claimed
US-20070043062-A1 Isoxazoles as peptide deformylase inhibitors ARPIDA A/S (DK) 2007-02-22 US disclosed
US-20070043062-A1 Isoxazoles as peptide deformylase inhibitors ARPIDA A/S (DK) 2007-02-22 US disclosed
US-20070043062-A1 Isoxazoles as peptide deformylase inhibitors ARPIDA A/S (DK) 2007-02-22 US disclosed
EP-1664000-A1 ISOXAZOLES AS PEPTIDE DEFORMYLASE INHIBITORS Arpida A/S (DK) 2006-06-07 EP disclosed
WO-2005026133-A1 ISOXAZOLES AS PEPTIDE DEFORMYLASE INHIBITORS ARPIDA A/S (DK) 2005-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043062-A1 Isoxazoles as peptide deformylase inhibitors PDF, MRPL21, PEPD SMN1; SMN2 3017/4885NPC1 1545/4885RAB9A 1592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.